Business context and reporting period
Medtronic plc is a global medical technology company operating in approximately 160 countries across four groups: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. This Form 10-K covers fiscal 2017, ended April 28, 2017—not fiscal 2016 Q4. Fiscal 2017 and fiscal 2015 had 52 weeks; fiscal 2016 had 53 weeks, with an extra selling week in Q1. Covidien was acquired in January 2015, affecting comparisons with fiscal 2015.
Financial performance and key metrics
| Metric | FY2017 | FY2016 |
|---|---|---|
| Net sales | $29.710 billion | $28.833 billion |
| Operating profit / margin | $5.330 billion / 17.9% | $5.291 billion / 18.4% |
| Net income attributable to Medtronic | $4.028 billion | $3.538 billion |
| Diluted EPS | $2.89 | $2.48 |
| Operating cash flow | $6.880 billion | $5.218 billion |
| Free cash flow (non-GAAP) | $5.626 billion | $4.172 billion |
| Gross margin | 68.7% | 68.3% |
Net sales rose 3% year over year; acquisitions contributed $200 million, while currency translation reduced sales by $34 million. Management also cited the extra fiscal 2016 selling week as a headwind to the comparison. Segment sales and growth were: Cardiac and Vascular $10.498 billion (+3%); Minimally Invasive Therapies $9.919 billion (+4%); Restorative Therapies $7.366 billion (+2%); and Diabetes $1.927 billion (+3%).
At April 28, 2017, cash, cash equivalents, and current investments were $13.708 billion; working capital was $10.316 billion and the current ratio was 1.7:1, excluding assets and liabilities held for sale. Total debt was $33.441 billion, including $7.520 billion current debt and $25.921 billion long-term debt. The company reported $6.880 billion operating cash flow and $1.254 billion capital expenditures. Dividends declared were $1.72 per share; share repurchases totaled $3.544 billion.
Fourth-quarter FY2017 sales were $7.916 billion, net income was $1.164 billion, and diluted EPS was $0.84, versus $7.567 billion, $1.104 billion, and $0.78, respectively, in fourth-quarter FY2016.
Material changes versus the prior comparable period
- GAAP diluted EPS increased 17%; non-GAAP diluted EPS rose 5%, to $4.60 from $4.37. Management attributed growth in part to revenue gains and more than $600 million in Covidien synergy savings realized since the acquisition.
- Operating profit grew only modestly and operating margin declined 0.5 percentage point. Fiscal 2017 included $300 million of certain litigation charges, compared with $26 million in FY2016; restructuring charges and intangible amortization also remained substantial.
- Operating cash flow increased $1.662 billion. Management cited higher receivable collections and lower cash payments for income taxes and interest.
- Interest expense, net fell to $728 million from $955 million, partly because FY2016 included debt-tender and interest-rate-swap charges. Total debt nevertheless increased to $33.441 billion from $31.102 billion.
- Pain Therapies sales declined 4%; other reported divisions and groups were flat to growing. FY2017 sales growth across U.S., non-U.S. developed, and emerging markets was 1%, 4%, and 7%, respectively.
Outlook, management commentary, risks, and unusual items
- No consolidated numerical FY2018 revenue or earnings guidance is provided in the supplied filing text. Management discussed continued focus on therapy innovation, expansion in international and emerging markets, value-based healthcare, and product launches, while identifying pricing, competition, reimbursement, procedure volumes, approvals, and currency as key variables.
- Medtronic agreed to sell its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal Health for $6.1 billion in cash, subject to adjustments; estimated after-tax proceeds were approximately $5.5 billion. Closing was expected in Q2 FY2018, subject to conditions. The businesses had $2.4 billion of sales in FY2017 and FY2016; the company anticipated improved growth, margins, and leverage, but cautioned that completion and expected benefits were uncertain.
- HeartWare was acquired for approximately $1.1 billion and Smith & Nephew’s gynecology business for approximately $350 million. The company expected approximately $850 million of Covidien-related synergies through FY2018.
- Material regulatory matters include an FDA consent decree covering the SynchroMed drug infusion system and Neuromodulation quality system, and FDA warning letters involving TYRX and HeartWare facilities. The filing also describes product-liability, patent, environmental, and government matters; accrued certain litigation charges were approximately $1.1 billion at year-end.
- Tax exposures include an IRS appeal of the Tax Court decision concerning allocation of income between Medtronic, Inc. and its Puerto Rico subsidiary, as well as other uncertain tax positions. The company reported $1.9 billion in gross unrecognized tax benefits.
- Management reported a global IT systems interruption in June 2017 that temporarily affected manufacturing and order fulfillment across a large portion of the business. Systems were restored, and management did not expect a material FY2018 effect.
- Other key risks include substantial leverage, healthcare cost containment and pricing pressure, product quality and clinical outcomes, regulatory changes, cybersecurity, supply interruptions, currency exposure, and acquisition/divestiture execution. Management stated that approximately $6 billion of cash and investments at certain U.S.-controlled non-U.S. subsidiaries may not be available for general corporate purposes, but expected available resources and its credit facilities to cover foreseeable needs for at least 12 months.
Most important facts for investors to verify
- Whether underlying sales and earnings growth persists after considering the FY2016 extra selling week, acquisitions, currency effects, and non-GAAP adjustments.
- Completion and proceeds of the Cardinal Health divestiture, and the effect of removing $2.4 billion in annual sales on the company’s growth, margins, and leverage.
- Progress on debt reduction and liquidity, including the $7.520 billion current debt balance and availability of cash held outside the U.S.
- Resolution and cash-cost implications of litigation, FDA compliance obligations, and outstanding tax disputes.
- Whether product launches—including the MiniMed 670G—translate into sustained adoption and growth amid competition and reimbursement constraints.